Russell Investments Group Ltd. Sells 63,796 Shares of Hologic, Inc. $HOLX

Russell Investments Group Ltd. reduced its stake in Hologic, Inc. by 28.5% in the 2nd quarter, selling 63,796 shares. The fund now owns 159,770 shares worth $10,406,000. Other institutional investors also modified their holdings. Hologic's stock opened at $74.82 with a market cap of $16.68 billion. The company reported $1.13 EPS for the quarter, beating estimates. Insiders, including the CEO, sold shares recently. Analysts have mixed ratings on the stock.

Russell Investments Group Ltd. reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 28.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 159,770 shares of the medical equipment provider's stock after selling 63,796 shares during the quarter. Russell Investments Group Ltd. owned about 0.07% of Hologic worth $10,406,000 as of its most recent SEC filing.

Time to buy these 3 healthcare companies that raised revenue guidance?

Other institutional investors have also modified their holdings of the company. Chung Wu Investment Group LLC purchased a new position in shares of Hologic in the 2nd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd lifted its position in Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider's stock worth $27,000 after buying an additional 273 shares during the last quarter. Zions Bancorporation National Association UT bought a new stake in Hologic in the first quarter worth $34,000. Cromwell Holdings LLC boosted its stake in Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock worth $38,000 after buying an additional 436 shares during the period. Finally, MAI Capital Management increased its position in Hologic by 121.4% during the second quarter. MAI Capital Management now owns 651 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 357 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Price Performance

Hologic stock opened at $74.82 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The stock has a market cap of $16.68 billion, a price-to-earnings ratio of 31.05, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65. The firm has a 50-day moving average of $71.77 and a two-hundred day moving average of $67.37. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $80.31.

Can Butterfly Network Spread its Wings in 2023?

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.03. The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company's revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.01 earnings per share. On average, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm's stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the sale, the director owned 47,336 shares of the company's stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 1.88% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on HOLX. Mizuho lowered shares of Hologic from an "outperform" rating to a "neutral" rating and raised their target price for the stock from $70.00 to $78.00 in a report on Thursday, October 23rd. BNP Paribas lowered shares of Hologic from a "strong-buy" rating to a "hold" rating and set a $79.00 price objective on the stock. in a research report on Friday, November 21st. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $78.00 price objective on shares of Hologic in a research note on Wednesday, October 22nd. Raymond James Financial cut Hologic from a "moderate buy" rating to a "hold" rating in a research note on Wednesday, October 22nd. Finally, Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a report on Wednesday, October 1st. Five equities research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $79.67.

View Our Latest Analysis on Hologic

Hologic Company Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Should You Invest $1,000 in Hologic Right Now?

Before you consider Hologic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.

While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here